Reuters logo
BRIEF-Adamas to present new ADS-5102 data from phase 2 trial
2017年2月17日 / 下午1点15分 / 8 个月前

BRIEF-Adamas to present new ADS-5102 data from phase 2 trial

Feb 17 (Reuters) - Adamas Pharmaceuticals Inc:

* Adamas to present new ADS-5102 data from phase 2 trial in walking impairment associated with multiple sclerosis at actrims forum 2017

* Adamas Pharmaceuticals- in study, patients on ads-5102 showed approximate 17 percent placebo-adjusted improvement in walking speed in timed 25 foot walk test

* Adamas Pharmaceuticals Inc - in study, patients on ADS-5102 showed approximate three second placebo-adjusted improvement in timed up and go (TUG) test

* Adamas Pharmaceuticals Inc - ADS-5102 was generally well tolerated

* Adamas Pharmaceuticals Inc - five ADS-5102 patients and no placebo patients discontinued treatment due to AES

* Adamas Pharmaceuticals Inc - most frequent adverse events (AES) reported in ads-5102 treatment group were dry mouth, constipation and insomnia Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below